# Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)

> **NCT01948986** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 36 (actual)

## Conditions studied

- Renal Impairment
- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Ertugliflozin

## Key facts

- **NCT ID:** NCT01948986
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-01
- **Primary completion:** 2014-10-06
- **Final completion:** 2014-10-16
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2019-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01948986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01948986, "Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01948986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*